CCDC13-AS2: A Potential Drug Target and Biomarker for Various Diseases

Target Name: CCDC13-AS2

NCBI ID: G729083

CCDC13-AS2

Other Name(s): LINC02158 | CCDC13 antisense RNA 2

CCDC13-AS2: A Potential Drug Target and Biomarker for Various Diseases

CCDC13-AS2 (LINC02158) is a protein that is expressed in various tissues of the body, including the brain, heart, lungs, and gastrointestinal tract. It is a member of the superfamily of transmembrane proteins, which means that it spans the cell membrane and extends into the space between cells. CCDC13-AS2 is also known as GFR伪13.5, and it is a potential drug target and biomarker for various diseases.

The GFR伪13.5 protein is a member of the G-protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play an important role in cellular signaling. GPCR signaling pathways involve the interaction between GPCRs and their ligands, which results in the production of various signaling molecules, such as neurotransmitters and ion channels. CCDC13-AS2 is thought to function as a negative regulator of GPCR signaling, which means that it works to reduce the activity of GPCRs.

One of the unique features of CCDC13-AS2 is its expression pattern in different tissues. It is highly expressed in the brain, where it is found in the postsynaptic density of neurons, and in the heart, where it is found in the cardiac muscle. It is also expressed in the lungs and the gastrointestinal tract, where it is involved in the regulation of cell signaling pathways that are important for respiratory and digestive function.

CDC13-AS2 is also a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, studies have shown that CCDC13-AS2 is overexpressed in various types of cancer, which suggests that it may be a useful target for cancer therapies. Additionally, CCDC13-AS2 has been shown to be involved in the regulation of neurotransmitter release from neurons, which may be important for the treatment of neurodegenerative diseases.

Another potential use for CCDC13-AS2 is as a drug target for treating cardiovascular disease. Studies have shown that CCDC13-AS2 is involved in the regulation of angiotensin signaling, which is a key factor in the development of cardiovascular disease. Additionally, CCDC13-AS2 has been shown to interact with several other proteins that are involved in cardiovascular disease, including the transcription factor FGF1 and the protein Pyroglobin. This suggests that CCDC13-AS2 may be a useful target for treating cardiovascular disease by modulating these signaling pathways.

In conclusion, CCDC13-AS2 is a protein that is expressed in various tissues of the body and is thought to function as a negative regulator of GPCR signaling. It is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. Further research is needed to fully understand the role of CCDC13-AS2 in these processes and to develop effective treatments based on this protein.

Protein Name: CCDC13 Antisense RNA 2

The "CCDC13-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC13-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets